Distinct characteristics of two intestinal protein compartments discriminated by using fenbendazole and a benzimidazole resistant isolate of Haemonchus contortus.
The intestine of Haemonchus contortus is hypersensitive to the effects of the anthelmintic fenbendazole (FBZ). The effects are postulated to stem from disruption of microtubules and interference with apical secretory vesicle transport, followed by release of digestive enzymes into the intestinal cell cytoplasm. Here, FBZ caused marker proteins for both apical (pepsinogen-like protease, PEP-1) and basal (cystatin-like protein) protein compartments to became homogeneously distributed in the cytoplasm of H. contortus intestinal cells. The observations with PEP-1 support the hypothesis that release of hydrolytic enzymes into the intestinal cell cytoplasm contributes to the mechanism of benzimidazole efficacy. A benzimidazole resistant isolate of H. contortus expressed type 1 and 2 intestinal beta-tubulin transcripts that would encode predominantly tyr200 and phe200 variants, respectively. This isolate was resistant to the known intestinal cell alterations induced by FBZ treatment in the susceptible isolate, including inhibition of apical vesicle transport. These results implicate type 1 beta-tubulin in mediating apical vesicle transport in intestinal cells and suggest that the tyr200 variant is a determinant of FBZ resistance in intestinal cells. In contrast, the basal protein compartment demonstrated sensitivity to FBZ treatment in these otherwise "resistant" worms. Hence, distinct FBZ-sensitive components appear to be involved in distributing intestinal proteins into the described apical and basal compartments of normal worms.
Shompole
Sankale
S
Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164-7040, USA.
Yao
Chaoqun
C
Cheng
Xiaoya
X
Knox
David
D
Johnson
Sandra
S
Jasmer
Douglas P
DP
D000818:Animals; D000918:Antibody Specificity; D000969:Antinematodal Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology; D015891:Cystatins / Q000276:immunology; D004351:Drug Resistance; D005273:Fenbendazole / Q000494:pharmacology*; D006189:Haemonchus / Q000033:anatomy & histology / Q000187:drug effects* / Q000648:ultrastructure; D007106:Immune Sera / Q000276:immunology; D007422:Intestines / Q000187:drug effects / Q000648:ultrastructure; D012697:Serine Endopeptidases / Q000276:immunology; D012756:Sheep; D014404:Tubulin / Q000235:genetics / Q000378:metabolism
D000969:Antinematodal Agents; D001562:Benzimidazoles; D015891:Cystatins; D007106:Immune Sera; D014404:Tubulin; D005273:Fenbendazole; C097082:Pep1 protein, mouse; D012697:Serine Endopeptidases